CAURIS CROISSANCE II FUND INVESTS IN CIPHARM
Cauris Croissance II Fund, managed by Cauris Management, the West African private equity fund manager, has acquired a stake in the capital of the pharmaceutical laboratory CIPHARM. The purpose of this investment is to finance the development of its injectable forms business.
About the CIPHARM laboratory
CIPHARM is the Ivorian leader in pharmaceutical production, present for more than 25 years in the production of generic medicines (dry forms, powders and syrups), under its own brand or under licence. The output of the CIPHARM laboratory is distributed in a dozen countries in West and Central Africa.
What does the Cauris Management investment in CIPHARM consist of?
The investment by Cauris Croissance II Fund will allow CIPHARM to broaden its offer by developing its injectable forms business, a market that local production does not serve sufficiently.
Commenting on the Cauris investment, Mr Ibrahima Diawara, Chairman of CIPHARM, said: « The entry of Cauris Croissance II Fund into the capital of CIPHARM will give the company a new dimension, in particular:
- higher business volumes thanks to the new investment and the launch of new products, including strategic ones such as haemodialysis solutions for patients with kidney failure;
- new technical partnerships;
- stronger corporate governance and better relations with the financial community »
« For Cauris Management, the partnership with CIPHARM is the opportunity to support the Ivorian leader in pharmaceutical production in its growth and diversification strategy. The economic and demographic growth of our countries brings a continuous rise in healthcare needs, which must be met by making quality care available at a reasonable cost. Cauris Management will also support CIPHARM in improving its environmental, social and governance practices », explains Mr Thierry Vissého Gnassounou, Partner at Cauris Management.
Is your company pursuing a growth project?
Tell us about it in five minutes.